Document Detail

Treatment of symptomatic uterine leiomyoma with letrozole.
MedLine Citation:
PMID:  18854113     Owner:  NLM     Status:  MEDLINE    
Uterine leiomyomas are the most common benign tumours of the female genital tract, often necessitating hysterectomy. The most common symptoms are dysmenorrhoea, menorrhagia, infertility and abortion. Ovarian hormones seem to play an essential role in pathogenesis, and deprivation of ovarian oestrogen causes leiomyomas to shrink significantly. The purpose of this study was to evaluate the effects of the non-steroidal aromatase inhibitor letrozole on uterine leiomyomas and on bone metabolism. A prospective, open clinical trial was conducted in a university-based hospital. Sixteen premenopausal women with symptomatic uterine leiomyomas were treated with letrozole 5 mg/day orally for 3 months. The main outcome measures of uterine and uterine leiomyoma sizes, serum FSH, LH, oestradiol concentrations, ovarian volumes and myoma-related symptoms were noted at baselines and once a month during treatment. Lumbar spine bone mineral density and biochemical markers of bone metabolism were studied at the beginning and at the end of 3 months. Letrozole significantly decreased uterine leiomyoma sizes (P < 0.01) and promptly benefited women with heavy menstrual bleeding associated with leiomyomas without changing bone mineral density. Aromatase inhibitors may represent a new generation of medications for the treatment of leiomyoma and associated symptoms. Larger clinical trials are needed, however, to fully evaluate their safety and efficacy.
Bilgin Gurates; Cem Parmaksiz; Gokhan Kilic; Husnu Celik; Selahattin Kumru; Mehmet Simsek
Related Documents :
12057733 - Differential effect of gonadotropin-releasing hormone analogue treatment on estrogen le...
17084673 - Pgd for aneuploidy screening: an expensive hoax?
25205803 - Death and interventional cardiology: a tale of two trials.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Reproductive biomedicine online     Volume:  17     ISSN:  1472-6491     ISO Abbreviation:  Reprod. Biomed. Online     Publication Date:  2008 Oct 
Date Detail:
Created Date:  2008-10-15     Completed Date:  2009-01-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101122473     Medline TA:  Reprod Biomed Online     Country:  England    
Other Details:
Languages:  eng     Pagination:  569-74     Citation Subset:  IM    
Department of Obstetrics and Gynecology, School of Medicine, Firat University, Elazig, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use
Aromatase Inhibitors / therapeutic use
Bone Density / drug effects
Bone and Bones / drug effects,  metabolism
Follicle Stimulating Hormone / blood
Leiomyoma / drug therapy*,  pathology
Luteinizing Hormone / blood
Nitriles / therapeutic use*
Organ Size / drug effects
Ovary / drug effects,  pathology
Pilot Projects
Triazoles / therapeutic use*
Tumor Burden / drug effects
Uterine Neoplasms / drug therapy*,  pathology
Uterus / drug effects,  pathology
Reg. No./Substance:
0/Antineoplastic Agents; 0/Aromatase Inhibitors; 0/Nitriles; 0/Triazoles; 112809-51-5/letrozole; 9002-67-9/Luteinizing Hormone; 9002-68-0/Follicle Stimulating Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Variability of endometrial glandular opening count in infertile patients prior to first IVF treatmen...
Next Document:  Short communication: Y chromosome microchimerism in female peripheral blood.